Paratek Pharmaceuticals to Report Second Quarter 2019 Financial Results on August 6, 2019
July 29, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, July 29, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Promotes Evan Loh, M.D. to Chief Executive Officer; Michael Bigham to Assume Role of Executive Chairman
June 25, 2019 16:01 ET
|
Paratek Pharmaceuticals
Adam Woodrow Promoted to President & Retains Chief Commercial Officer Position Randy Brenner Promoted to Chief Development & Regulatory Officer BOSTON, June 25, 2019 (GLOBE NEWSWIRE) -- ...
Paratek’s NUZYRA™ (omadacycline) Generates Net Sales of $1.3 Million in the First Eight Weeks on the U.S. Market
May 08, 2019 16:05 ET
|
Paratek Pharmaceuticals
-- Approximately One Third of Commercial Lives in U.S. had Access to NUZYRA by the End of the First Quarter 2019 -- -- Significant Presence at ECCMID 2019 with Nine NUZYRA Presentations -- BOSTON,...
Paratek Pharmaceuticals to Report First Quarter 2019 Financial Results on May 8, 2019
April 30, 2019 16:05 ET
|
Paratek Pharmaceuticals
BOSTON, April 30, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Broadens Clinical Profile of NUZYRA™ (Omadacycline) with New ECCMID 2019 Data Presentations
April 15, 2019 16:30 ET
|
Paratek Pharmaceuticals
- New microbiology data reinforce activity of NUZYRA against broad range of pathogens commonly associated with community-acquired infections - Study supports no dose adjustments in patients based on...
Paratek Pharmaceuticals Presenting New Data from NUZYRA™ (Omadacycline) Development Program at ECCMID 2019
April 04, 2019 08:30 ET
|
Paratek Pharmaceuticals
BOSTON, April 04, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Receives American Chemical Society 2019 Heroes of Chemistry Award
April 01, 2019 09:05 ET
|
Paratek Pharmaceuticals
BOSTON, April 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals to Present at the 2019 H.C Wainwright Global Life Sciences Conference
March 28, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 28, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Pharmaceuticals Announces Management Change
March 18, 2019 08:00 ET
|
Paratek Pharmaceuticals
BOSTON, March 18, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
March 01, 2019 16:30 ET
|
Paratek Pharmaceuticals
BOSTON, March 01, 2019 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative...